Physician profile
Eman Ayed Abusalah
NPI 1043915812
$2,307.55
in general payments reported to CMS, 2019-2025
14 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $390 · 2024: $498 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,307.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $467.59 | 2023-2025 | Breztri |
| Abbvie INC. | $344.84 | 2023-2025 | Vraylar |
| Glaxosmithkline, LLC. | $343.48 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $264.34 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $164.56 | 2023-2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $158.96 | 2025 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.94 | 2023-2025 | Caplyta |
| Novo Nordisk INC | $135.04 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $102.65 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $55.96 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $41.31 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.62 | 2023-2024 | Xifaxan |
| Tms Neurohealth Centers INC. | $19.88 | 2025 | Tms Neurohealth Centers INC. |
| Cipher Pharmaceuticals US LLC | $14.38 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eman Abusalah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.